Nkarta to Present at Upcoming Investor Conference
Nkarta, a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, announced its participation in the Raymond James Human Health Innovation Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta, a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, announced its participation in the Raymond James Human Health Innovation Conference. The event is scheduled for June 21, 2021, featuring a fireside chat presentation at 3:20 p.m. ET. A live webcast will be available on Nkarta's website, with a replay accessible for approximately four weeks thereafter. The company is advancing allogeneic NK cell therapies through innovative manufacturing processes designed to enhance tumor targeting and persistence.
Details
News Market Reaction – NKTX
The recorded move for NKTX in the trading session of this news was +4.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:
Raymond James Human Health Innovation Conference
June 21, 2021
3:20 p.m. ET - fireside chat presentation
The live webcast of the presentation will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of the webcast will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.